Department of Hepatobiliary and Pancreatic Surgery, Yonsei University College of Medicine, Seoul, Korea.
Pancreatobiliary Cancer Clinic, Yonsei Cancer Center, Severance Hospital, Seoul, Korea.
Ann Surg Oncol. 2020 Dec;27(13):5235-5236. doi: 10.1245/s10434-020-08670-9. Epub 2020 May 31.
Pancreatic adenocarcinoma is a lethal condition with poor outcomes and an increasing incidence.1 However, recent meta-analysis reported improved survival and R0 resection rate following neoadjuvant chemotherapy with subsequent surgery in initially unresectable pancreatic cancer.2 In addition, as a result of technological advances during the past 2 decades, even in pancreatic cancers, minimally invasive surgery (MIS) approaches are being used more frequently and safely.35 This video shows the feasibility and safety of laparoscopic resection in advanced left-sided pancreatic cancer.
The patient was a 63-year-old male with hypertension and diabetes. Initial computed tomography (CT) scan showed a 31 mm-sized pancreatic tail cancer with celiac artery and left adrenal gland abutment. The patient underwent neoadjuvant chemotherapy due to the risk of retroperitoneal cancer infiltration. After four cycles of FOLFIRINOX chemotherapy, follow-up CT scan showed the tumor decreased to 2.6 cm and celiac artery abutment became less prominent. Based on the CT scan, laparoscopic radical distal pancreatosplenectomy with left adrenalectomy was planned.
A five-port laparoscopic approach was performed, including three 12 mm trocars and an additional two 5 mm trocars. Initial intra-abdominal exploration showed no peritoneal seeding or micro liver metastasis. Gastric wedge resection was added due to cancer invasion for margin-negative resection. Operation time was 215 min and estimated blood loss was 200 cc without transfusion. The patient was discharged on postoperative day 6 without any complications, including postoperative pancreatic fistula.
Laparoscopic distal pancreatosplenectomy can be technically feasible and safe to obtain negative resection margins in well-selected patients following neoadjuvant therapy in locally advanced pancreatic cancer.6.
胰腺腺癌是一种致命疾病,预后差,发病率不断上升。1 然而,最近的荟萃分析报告称,在最初不可切除的胰腺癌患者中,新辅助化疗后进行手术可改善生存和 R0 切除率。2 此外,由于过去 20 年技术的进步,即使在胰腺癌症中,微创外科(MIS)方法也越来越多地被安全地使用。35 本视频展示了腹腔镜在进展期左侧胰腺腺癌中的可行性和安全性。
患者为 63 岁男性,患有高血压和糖尿病。初始计算机断层扫描(CT)显示胰腺尾部有一个 31mm 大小的癌症,与腹腔动脉和左肾上腺相邻。由于腹膜后癌症浸润的风险,患者接受了新辅助化疗。在 FOLFIRINOX 化疗四个周期后,随访 CT 扫描显示肿瘤缩小至 2.6cm,腹腔动脉相邻程度减轻。根据 CT 扫描,计划进行腹腔镜根治性远端胰脾切除术和左肾上腺切除术。
采用五孔腹腔镜方法,包括三个 12mm 套管针和另外两个 5mm 套管针。初步腹腔探查未发现腹膜播种或微小肝转移。由于癌症侵犯,进行胃楔形切除以获得阴性切缘。手术时间为 215 分钟,估计失血量为 200cc,无需输血。患者术后第 6 天无并发症出院,包括术后胰瘘。
在局部进展期胰腺腺癌患者中,经过新辅助治疗后,腹腔镜远端胰脾切除术在技术上是可行的,并且在选择合适的患者中可以安全获得阴性切缘。6.